Mindfulness Approaches for Living After Breast Cancer
(HEAL-ABC Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and an app-based, self-paced version (MAPs App). Participants will include younger breast cancer survivors (BCS) who were diagnosed with breast cancer at or before age 50 years, have completed their primary cancer treatment (i.e., surgery, radiation, and/or chemotherapy) at least 6 months earlier, and report elevated depressive symptoms.
Are You a Good Fit for This Trial?
This trial is for female breast cancer survivors who were diagnosed at or before age 50, have finished primary treatment between 6 months and 5 years ago, and are experiencing some depression. They must score within a specific range on a depression questionnaire, be able to use digital devices, understand English or Spanish, and consent to participate in a mindfulness program.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants engage in mindfulness-based interventions either through live online sessions or a digital app over a 6-week period
Post-intervention Assessment
Participants' depressive symptoms are assessed using the CES-D score 2 weeks after the intervention
Follow-up
Participants are monitored for depressive and fatigue symptoms over time
What Are the Treatments Tested in This Trial?
Interventions
- Mindfulness (MAPs) Digital App
- Mindfulness (MAPs) Live Online
Find a Clinic Near You
Who Is Running the Clinical Trial?
NRG Oncology
Lead Sponsor
National Cancer Institute (NCI)
Collaborator